Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Hodgkin Lymphoma and T/NK Cell Lymphoma Hodgkin Lymphoma and T/NK Cell Lymphoma

624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in T/NK Cell Lymphoma

Watch Session

39 Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.

 

40 Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Alison J. Moskowitz, Neha Mehta-Shah, et al.

 

41 Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Neha Mehta-Shah, Ajitha Kommalapati, Stephanie Teja, et al.

 

42 Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Yan Gao, MD, Huiqiang Huang, Xiaoxiao Wang, et al.

 

43 Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Christiane Querfeld,  Basem M. William, Lubomir Sokol, et al.

 

44 Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results according to ASH clinically relevant abstract

Barbara Pro, Jonathan E. Brammer, Carla Casulo, et al.